3 articles with AbCellera
AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment
AbCellera today announced that LY-CoV555, the lead antibody from the collaboration between AbCellera and Eli Lilly and Company (Lilly), has entered into human testing for the potential treatment of COVID-19.
AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform
AbCellera provides pharma and biotech partners with an AI-powered, full-stack drug discovery platform to accelerate development of biologics
AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets.